MusclePharm Corp.

MusclePharm Corp. is a healthy lifestyle company that develops and manufactures nutritional supplements that address active lifestyles, including muscle building, weight loss and the maintenance of general fitness through a daily nutritional supplement regimen that was founded by former NFL player Brad Pyatt. The products are formulated through a six-stage research process using the expertise of leading nutritional scientists. MusclePharm's products are sold to consumers in more than 110 countries and available in over 10,500 U.S. retail outlets and globally through more than 100 online channels.

Expert Comments:

Andrew Labutka, Seeking Alpha (1/5/15)
"The outlook for MusclePharm Corp. appears to be very bright, as I expect the company to tally its first full-year operating gain in 2015. Based on my analysis, shares of MusclePharm are currently trading at a 29% discount to fair market value."

Mark Phillips, Seeking Alpha (12/16/14)
"MusclePharm Corp. is still showing over 100% YOY growth in the international channel. . .the Biozone acquisition has started contributing to revenue growth. . .Q4/14 will be the first quarter two of MusclePharm's products (Arnold Iron Whey and Arnold Iron Pump) will be available in approximately 3,500 Walmart locations. . .with cheap financing available, a low enterprise value and global M&A deals at the highest level in seven years, I believe many healthcare consumer-focused companies may be interested in acquiring MusclePharm. . .the stock is deeply oversold at current levels. . .the Q3/14 market overreaction has created a tremendous buying opportunity for investors with a long-term mindset."

"MusclePharm Corp.'s stock price has moved up substantially since we did an offering in February 2013 at $4/share. The stock is now trading at just under $11/share. The company's public announcements have been good, and the revenues have continued to grow, with about $105M on the top line last year. The company has made progress toward profitability. . .

MusclePharm has definitely proven itself a very capable marketing machine. It is very good at anticipating what products the market will be looking for, and it has been able to grow its sales. I know the company has done a substantial amount of work on corporate governance, and processes and procedures. I'm hopeful that MusclePharm will be able to attain sustained profitability in the near future. . ." read more >

Keay Nakae, Ascendiant Capital Markets (11/17/14)
"MusclePharm Corp.'s Q3/14 net revenue was $47.8M (+74% pro forma), which was $1.1M higher than consensus. . .the revenue growth in Q3/14 was driven by a number of factors, which we expect will continue to drive the topline in 2014. . .there is upside to the company relative to the current price."

Mark Phillips, Seeking Alpha (10/22/14)
"New product launches in large and growing markets in late 2014 and 2015 provide an additional catalyst to MusclePharm Corp. shares. If the company is not acquired in the near term, investors could be looking at a multibagger over the next three to five years."

Paulo Santos, Seeking Alpha (10/6/14)
"Today, MusclePharm Corp. announced it bought back 250K shares of its own stock for $10/share. . .it highlights the new nature of the company: MusclePharm is now a regular company that tries to avoid dilution as much as possible versus its former self that even paid suppliers with stock. . .this move also portrays confidence in near-term financial developments."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
MusclePharm Corp. Content